ArticleEuropean journal of epidemiology2014
Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism.
Article in European journal of epidemiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Metabolomics in stress-related disorders: a systematic review and bioinformatics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers.Clinical and translational science · 2024Trial
- Trial
- Determinants of the plasma metabolome: cross-sectional and longitudinal associations over six years in the NESDA cohort.EBioMedicine · 2026Article
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease.Nature communications · 2026Article
- Longitudinal analysis of genetic and environmental interplay in human metabolic profiles and the implication for metabolic health.Genome medicine · 2025Article
- Metabolomic signatures of cognitive function in a type 2 Diabetes-Enriched cohort.Scientific reports · 2025Article
- Article
- Interlaboratory comparison of standardised metabolomics and lipidomics analyses in human and rodent blood using the MxPbioRxiv : the preprint server for biology · 2024Article
- Identification of metabolites reproducibly associated with Parkinson's Disease via meta-analysis and computational modelling.NPJ Parkinson's disease · 2024Article
- Cross-sectional analyses of metabolites across biological samples mediating dietary acid load and chronic kidney disease.iScience · 2024Article
- A facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate.Results in chemistry · 2024Article
- The determinants of fasting and post-load non-esterified fatty acids in older adults: The cardiovascular health study.Metabolism open · 2023Article
- Metabolomic biomarkers of habitual B vitamin intakes unveil novel differentially methylated positions in the human epigenome.Clinical epigenetics · 2023Article
- Mendelian Randomization Study of Lipid Metabolites Reveals Causal Associations with Heel Bone Mineral Density.Nutrients · 2023Article
- Nontargeted Metabolomics Revealed Novel Association Between Serum Metabolites and Incident Acute Coronary Syndrome: A Mendelian Randomization Study.Journal of the American Heart Association · 2023Article
- Demographic, Health and Lifestyle Factors Associated with the Metabolome in Older Women.Metabolites · 2023Article
- Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.Metabolites · 2022Article
- Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers.PloS one · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs' action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and--based on the associations found--to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.